MMP-9-IN-1 | whatman (沃特曼)

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

MMP-9-IN-1 纯度: 99.74%

MMP-9-IN-1 是一种特异性的基质金属蛋白酶-9 (MMP-9) 抑制剂，选择性靶向 MMP-9 的血红素 (PEX) 域，但不作用于其他 MMP。

MMP-9-IN-1 Chemical Structure

CAS No. : 502887-71-0

规格	价格	是否有货
10 mM * 1 mL in DMSO	￥2840	In-stock
5 mg	￥3500	In-stock
10 mg	￥5500	In-stock
50 mg		询价
100 mg		询价

* Please select Quantity before adding items.

MMP-9-IN-1 相关产品

•相关化合物库:

Bioactive Compound Library Plus
Metabolism/Protease Compound Library
Anti-Cancer Compound Library
Differentiation Inducing Compound Library
Anti-Pancreatic Cancer Compound Library
Angiogenesis Related Compound Library
Targeted Diversity Library

生物活性

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs^[1].

IC₅₀ & Target^[1]

MMP-9

体外研究
(In Vitro)

MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity^[1].
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	COS-1 monkey epithelial cell lines
Concentration:	100 μM
Incubation Time:	24 hours
Result:	Treatment did not cause notable cytotoxicity.

Cell Proliferation Assay^[1]

Cell Line:	HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
Concentration:	10 μM
Incubation Time:	9 days
Result:	Significant inhibition of cell proliferation.

体内研究
(In Vivo)

MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1].
MMP-9-IN-1 inhibits cancer cell metastasis in vivo^[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1]
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

分子量

369.39

Formula

C₁₆H₁₇F₂N₃O₃S

CAS 号

502887-71-0

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

In Vitro:

DMSO : 125 mg/mL (338.40 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7072 mL	13.5358 mL	27.0717 mL
5 mM	0.5414 mL	2.7072 mL	5.4143 mL
10 mM	0.2707 mL	1.3536 mL	2.7072 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 50% PBS

Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil

Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.63 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在上海金畔生物科技有限公司网站选购。

参考文献

[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务